Last reviewed · How we verify
14DPQ
14DPQ, marketed by Menzies School of Health Research, is a small molecule with an undisclosed mechanism of action, currently holding a niche position in its therapeutic area. The drug's key strength lies in its protected intellectual property, with the key composition patent expiring in 2028. The primary risk is the lack of detailed public information on its mechanism and clinical trial results, which may limit its broader adoption and competitive positioning.
At a glance
| Generic name | 14DPQ |
|---|---|
| Sponsor | Menzies School of Health Research |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess Current Standard Malaria Treatment Guidelines in the Republic of the Sudan (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 14DPQ CI brief — competitive landscape report
- 14DPQ updates RSS · CI watch RSS
- Menzies School of Health Research portfolio CI